Nurix Therapeutics (NASDAQ: NRIX) has recently received a number of price target changes and ratings updates:
- 6/18/2026 – Nurix Therapeutics had its price target raised by Robert W. Baird from $26.00 to $33.00. They now have an “outperform” rating on the stock.
- 6/15/2026 – Nurix Therapeutics had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $34.00 price target on the stock.
- 6/10/2026 – Nurix Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $32.00 price target on the stock.
- 6/9/2026 – Nurix Therapeutics had its price target raised by BTIG Research from $30.00 to $32.00. They now have a “buy” rating on the stock.
- 6/8/2026 – Nurix Therapeutics had its price target raised by Truist Financial Corporation from $30.00 to $32.00. They now have a “buy” rating on the stock.
- 6/8/2026 – Nurix Therapeutics was downgraded by Wells Fargo & Company from “overweight” to “hold”. They now have a $25.00 price target on the stock, down from $28.00.
- 6/8/2026 – Nurix Therapeutics had its price target raised by Jefferies Financial Group Inc. from $41.00 to $45.00. They now have a “buy” rating on the stock.
- 6/8/2026 – Nurix Therapeutics had its price target raised by Needham & Company LLC from $26.00 to $34.00. They now have a “buy” rating on the stock.
- 5/18/2026 – Nurix Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $30.00 price target on the stock.
- 4/27/2026 – Nurix Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $32.00 price target on the stock.
Insider Buying and Selling at Nurix Therapeutics
In other Nurix Therapeutics news, insider Gwenn Hansen sold 5,394 shares of Nurix Therapeutics stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $20.00, for a total transaction of $107,880.00. Following the completion of the transaction, the insider directly owned 115,005 shares of the company’s stock, valued at $2,300,100. The trade was a 4.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Houte Hans Van sold 14,055 shares of the company’s stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $16.60, for a total transaction of $233,313.00. Following the completion of the transaction, the chief financial officer owned 37,592 shares in the company, valued at approximately $624,027.20. This represents a 27.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 25,051 shares of company stock valued at $434,466 in the last ninety days. Insiders own 6.70% of the company’s stock.
The company’s pipeline includes multiple programs in various stages of development.
Featured Stories
- Five stocks we like better than Nurix Therapeutics
- Data Center Delays Create Opportunity in These 3 Stocks
- Uncle Sam Plugs In: Nuclear Energy’s Cash Flow Moment Is Finally Here
- Fabrinet Is Becoming a Quiet Winner in the AI Optics Buildout
- 3 Stocks Building the Future of Agentic AI Payments
Receive News & Ratings for Nurix Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.
